Europe
RefluxStop™ is CE marked in Europe. It is currently available in:
- Austria
- France
- Italy
- Germany
- Norway
- Spain
- Sweden
- Switzerland
- United Kingdom
Implantica presents a robust health economic analysis of RefluxStop™ conducted by University of York, UK
22.08.2022
| Non regulatory
Implantica AG (publ), a MedTech company at the forefront of the upcoming eHealth revolution, has received from University of York’s (UK) Health Economics Consortium an in-depth and comprehensive health economic analysis for RefluxStop™ versus alternative surgical and medical treatments.
This rigorous analysis clearly shows the superior cost-effectiveness of RefluxStop™ against other anti-reflux medical and surgical treatment interventions (including Standard of Care fundoplication, Magnetic augmentation device and PPI medical treatment).
The outcome of this assessment highlights RefluxStop™ as superior compared to all other therapies in quality-of-life outcomes.
“This is excellent news for RefluxStop’s commercial development as it will be considered by governmental bodies and insurance companies worldwide. Economic efficiency is an increasingly important decision-making factor in reimbursement in several major European countries as well as Canada and the USA. University of York in the UK is a highly renowned center for health economic analysis. The importance of this outcome should not be underestimated,” says Peter Forsell, CEO of Implantica.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]
The information was sent for publication, through the agency of the contact person set out above, on August 22, 2022, at 8:30 a.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
Newsroom